CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results
August 09, 2017 16:31 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results
May 10, 2017 17:06 ET | Cidara Therapeutics, Inc.
SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
2019 logo_150x35_jpg.jpg
Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
April 12, 2017 06:06 ET | Novan, Inc.
MORRISVILLE, N.C., April 12, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced positive topline results from the Company’s Phase 2 clinical trial with...
CidaraLogo (1).jpg
Cidara Therapeutics to Host Investor Day on April 6, 2017
March 29, 2017 07:30 ET | Cidara Therapeutics, Inc.
SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
March 15, 2017 17:22 ET | Cidara Therapeutics, Inc.
SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
February 21, 2017 07:30 ET | Cidara Therapeutics, Inc.
Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track ...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
November 10, 2016 16:10 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Therapeutics to Present at the Stifel 2016 Healthcare Conference
November 08, 2016 16:05 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced it will...
CidaraLogo (1).jpg
Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility
November 02, 2016 07:30 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other...
CidaraLogo (1).jpg
Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares
October 13, 2016 09:20 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the closing...